PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

ClinicalTrials.gov ID: NCT02653625

Public ClinicalTrials.gov record NCT02653625. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open label, proof of concept (PoC) study of Cenicriviroc (CVC) in adult participants with Primary Sclerosing Cholangitis (PSC). The main objective of this PoC study is to assess changes in alkaline phosphatase (ALP) both individually and as a group, over 24 weeks of treatment with CVC.

Study identification

NCT ID: NCT02653625
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Tobira Therapeutics, Inc.; Industry
Enrollment: 24 participants

Conditions and interventions

Conditions

Primary Sclerosing Cholangitis

Interventions

Cenicriviroc 150 mg Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 14, 2016 (Actual)
Primary completion: Aug 31, 2017 (Actual)
Completion: Aug 31, 2017 (Actual)
Last update posted: Oct 1, 2018

2016 – 2017

United States locations

U.S. sites: 5
U.S. states: 3
U.S. cities: 5

Facility	City	State	ZIP	Site status
Scripps Clinic	La Jolla	California	92037	—
University of California, Davis Medical Center	Sacramento	California	95817	—
Sutter Health, California Pacific Medical Center	San Francisco	California	94115	—
University of Miami	Miami	Florida	33136	—
Icahn School of Medicine	New York	New York	10029	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02653625, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 1, 2018 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02653625 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →